IP Library Granted Patent US 8,252,326
Granted Patent B2
US 8,252,326 · App. 11/141,774 · Granted Aug 28, 2012

Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10

Assignee: Catalent Australia Pty Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,326
App. No.
11/141,774
Granted
Aug 28, 2012
Kind
B2
Abstract

The invention includes dosage formulations, dosage forms and related methods for providing oral dosage forms of low solubility active ingredients such as coenzyme Q10. The present invention includes a Self-Microemulsifying Drug Delivery System (SMEDDS) in the form of a self-microemulsifying mixture that comprises a combination of a hydrophilic surfactant and a lipophilic co-surfactant (forming a surfactant pair). The preferred surfactant pair comprises a hydrophilic surfactant and a lipophilic co-surfactant with respective HLB (Hydrophile-Lipophile Balance) values of more than 12 and less than 8 respectively. The systems also contain at least one lipophilic solvent. The formulations exhibited excellent dissolution properties and storage stability.

Claims (28)

1. A soft capsule containing an active ingredient comprising the active ingredient contained in a stable self-microemulsifying mixture, said mixture comprising:

(1) at least one hydrophilic surfactant having a hydrophile-lipophile balance of greater than 12;

(2) at least one lipophilic co-surfactant having a hydrophile-lipophile balance of less than 8; and

(3) at least one hydrophobic solvent;

wherein the weight ratio of said at least one hydrophilic surfactant to said at least one lipophilic co-surfactant is in the range of from 30:1 to 3:1;

wherein the concentration of said at least one hydrophobic solvent in said self-microemulsifying mixture is in the range of from 2 to 50% by weight and comprises a mixture of isopropyl myristate and lemon oil or a mixture of isopropyl myristate and orange oil; and

wherein the self-microemulsifying mixture exhibits a dissolution of up to 100% and storage stability of more than 80 days.

2. The soft capsule according to claim 1 , wherein the concentration of said at least one hydrophilic surfactant in said self-microemulsifying mixture is in the range of from 20 to 70% by weight.

3. The soft capsule according to claim 1 , wherein the concentration of said at least one lipophilic co-surfactant in said self-microemulsifying mixture is in the range of from 1.5 to 50% by weight.

4. The soft capsule according to claim 1 , wherein said mixture is substantially free of water.

5. The soft capsule according to claim 1 additionally comprising optionally at least one hydrophilic solvent.

6. The soft capsule according to claim 5 , wherein said at least one hydrophilic solvent is selected from the group consisting of glycol ethers.

7. The soft capsule according to claim 5 , wherein the weight ratio of said hydrophilic solvent to the total of said at least one hydrophilic surfactant, said at least one lipophilic co-surfactant and said at least one hydrophobic solvent is about 0.02-1:1.

8. A soft capsule containing a dosage form of a low water-solubility active ingredient comprising: at least one low water-solubility active ingredient contained in a stable self-microemulsifying mixture, said mixture comprising:

(1) at least one hydrophilic surfactant having a hydrophile-lipophile balance of greater than 12;

(2) at least one lipophilic co-surfactant having a hydrophile-lipophile balance of less than 8; and

(3) at least one hydrophobic solvent

wherein the weight ratio of said at least one hydrophilic surfactant to said at least one lipophilic co-surfactant is in the range of from 30:1 to 3:1;

wherein the concentration of said at least one hydrophobic solvent in said self-microemulsifying mixture is in the range of from 2 to 50% by weight and comprises a mixture of isopropyl myristate and lemon oil or a mixture of isopropyl myristate and orange oil; and

wherein the self-microemulsifying mixture exhibits a dissolution of up to 100% and storage stability of more than 80 days.

9. A soft capsule containing a dosage form of coenzyme Q10 comprising: coenzyme Q10 contained in a stable self-microemulsifying mixture, said mixture comprising:

(1) at least one hydrophilic surfactant having a hydrophile-lipophile balance of greater than 12;

(2) at least one lipophilic co-surfactant having a hydrophile-lipophile balance of less than 8; and

(3) at least one hydrophobic solvent;

wherein the weight ratio of said at least one hydrophilic surfactant to said at least one lipophilic co-surfactant is in the range of from 30:1 to 3:1;

wherein the concentration of said at least one hydrophobic solvent in said self-microemulsifying mixture is in the range of from 2 to 50% by weight and comprises a mixture of isopropyl myristate and lemon oil or a mixture of isopropyl myristate and orange oil; and

wherein the self-microemulsifying mixture exhibits a dissolution of up to 100% and storage stability of more than 80 days.

10. The soft capsule according to claim 9 , wherein the capsule wall is a non-gelatin composition.

Assignments (2)
CHANGE OF NAME Recorded Jul 25, 2012
From: CARDINAL HEALTH 401 AUSTRALIA PTY LTD.
To: CATALENT AUSTRALIA PTY LTD.
Reel/Frame 028640/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2007
From: LIN, JING
To: CARDINAL HEALTH 401 AUSTRALIA PTY LTD.
Reel/Frame 019911/0470 →
Continuity (1)
Related Publication 20060275358A1 · Dec 7, 2006